Marc R. Larochelle MD, MPH

Associate Professor, General Internal Medicine

801 Massachusetts Ave | (617) 414-7399
Marc Larochelle
Sections

General Internal Medicine

Centers

Clinical Addiction Research and Education Unit

Biography

Marc Larochelle is a general internist and clinical investigator specializing in addiction medicine at BMC and an assistant professor of medicine at BUSM. Larochelle's clinical and research interests focus on the safety of opioid prescribing and the recognition and treatment of opioid use disorders. As a health services researcher, Larochelle aims to leverage insights from large data sources and translate the findings into interventions that improve the quality and value of health care delivered. His special interests are Primary Care and Addiction Medicine.

Education

Medicine-Internal, MD, University of Pittsburgh School of Medicine

Clinical Evaluation/Research, MPH, Harvard School of Public Health

Biomedical Engineering, BSE, Duke University

Publications

Published on 5/22/2025

Oles WC, Liu M, Wakeman SE, Larochelle MR. Geographic Trends in Opioid and Polysubstance Overdose Deaths in the US, 2014-2023. J Gen Intern Med. 2025 May 22. PMID: 40402363.

Published on 4/11/2025

Gilbert L, Chahine R, Chandler R, Feaster DJ, Kim E, Aldridge A, Bagley S, Balvanz P, Fernandez S, Rock P, Vickers-Smith RA, Villani J, Battaglia T, Brown J, Bush H, Chase RP, Collins T, D'Costa L, Damato-MacPherson C, David JL, Defiore-Hyrmer J, Freeman PR, Glasgow L, Hammerslag LR, Hotchkiss J, Hunt T, Hussain S, Kamanu V, Knott C, Knudsen HK, LaRochelle M, Laudate A, Lyons M, McMullan J, Nakayima J, Schackman BR, Slavova S, Tan S, Vandergrift N, Walters ST, Westgate PM, Wu E, Young AM, Zarkin GA, Freisthler B, Oga E, Samet JH, Walsh SL, Winhusen J, Jackson R, El-Bassel N. The effectiveness of the communities that HEAL intervention on reducing non-fatal opioid overdoses: A prespecified secondary analysis of a waitlist cluster control randomized controlled trial. Int J Drug Policy. 2025 Jun; 140:104798. PMID: 40220509.

Published on 4/3/2025

Jayasinghe T, Drainoni ML, Walley A, Grella C, Majeski A, Rolles A, Cogan A, Venkatesan G, Stein MD, Larochelle M, Samet JH, Kimmel SD. "Every Time I Go in There, It Gives Me Time to Reflect": A Qualitative Study of Patient Perspectives on Substance Use, Medications for Opioid Use Disorder, and Harm Reduction Following Hospitalization for Serious Injection-Related Infection. Open Forum Infect Dis. 2025 May; 12(5):ofaf201. PMID: 40352630.

Published on 3/19/2025

Lodi S, Yan S, Bovell-Ammon B, Christine PJ, Hsu HE, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz JM, Walley AY, Larochelle MR. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational data. Addiction. 2025 Mar 19. PMID: 40104887.

Published on 2/28/2025

Tilhou AS, Gasman S, Wang J, Standish K, White LF, Cogan A, Devlin M, Larochelle M, Adams WG. Assessing inequities in buprenorphine treatment across the care cascade. Drug Alcohol Depend. 2025 May 01; 270:112636. PMID: 40043350.

Published on 2/9/2025

Bayly R, Cordes J, Bernson D, Ackerson LK, LaRochelle MR, Hassan GH, Bauer CX, Stopka TJ. Predicting fatal opioid-involved overdoses: A social-ecological framework matched to a linked-data warehouse. Int J Drug Policy. 2025 Mar; 137:104730. PMID: 39929056.

Published on 2/5/2025

Magane KM, Saitz R, Fielman S, LaRochelle MR, Shanahan CW, Pace CA, LaValley M, Penington K, Karzhevsky S, Hurstak E. Supporting primary care clinicians in caring for patients with alcohol use disorder: study protocol for Records for Alcohol Care Enhancement (RACE), a factorial four-arm randomized trial. Addict Sci Clin Pract. 2025 Feb 05; 20(1):9. PMID: 39910606.

Published on 11/8/2024

Rosenmoss S, LaRochelle M, Bearnot B, Weinstein Z, So-Armah K, Moyo P, Yan S, Walley AY, Kimmel SD. Racial and Ethnic Disparities in Referral Rejection From Postacute Care Facilities Among People With Opioid Use Disorder in Massachusetts. J Addict Med. 2025 Mar-Apr 01; 19(2):165-171. PMID: 39514897.

Published on 9/9/2024

Fareed N, Olvera RG, Wang Y, Hayes M, Larimore EL, Balvanz P, Langley R, Noel CA, Rock P, Redmond D, Neufeld J, Kosakowski S, Harris D, LaRochelle M, Huerta TR, Glasgow L, Oga E, Villani J, Wu E. Lessons Learned From Developing Dashboards to Support Decision-Making for Community Opioid Response by Community Stakeholders: Mixed Methods and Multisite Study. JMIR Hum Factors. 2024 Sep 09; 11:e51525. PMID: 39250216.

Published on 8/1/2024

Christine PJ, Chahine RA, Kimmel SD, Mack N, Douglas C, Stopka TJ, Calver K, Fanucchi LC, Slavova S, Lofwall M, Feaster DJ, Lyons M, Ezell J, Larochelle MR. Buprenorphine Prescribing Characteristics Following Relaxation of X-Waiver Training Requirements. JAMA Netw Open. 2024 Aug 01; 7(8):e2425999. PMID: 39102264.

View full list of 112 publications.